二氢吡啶类钙通道抑制剂与缺氧关联的药物警戒研究
该研究基于WHO药物警戒数据库VigiBase,采用不成比例分析评估二氢吡啶类钙通道抑制剂(DCCI)与缺氧的报告关联。结果显示静脉氯维地平和尼卡地平存在统计学显著的缺氧信号,中位起病时间2天,尼卡地平停药后症状缓解;口服尼卡地平未发现信号。
要点
- 静脉氯维地平和尼卡地平与缺氧存在显著报告关联。
- 缺氧中位起病时间2天,尼卡地平停药后症状可缓解。
- 口服尼卡地平未发现缺氧信号,提示给药途径可能影响风险。
核心结论
- 药物警戒数据库分析显示静脉DCCI使用与缺氧存在显著关联。
研究设计与样本
- 基于WHO药物警戒数据库VigiBase的不成比例分析,评估静脉氯维地平和尼卡地平与缺氧的报告关联,并描述病例特征。
主要发现
- 静脉氯维地平和尼卡地平检测到统计学显著的缺氧信号。
- 缺氧起病时间中位数为2天(四分位距1.5-4.5)。
- 静脉尼卡地平有4例停药后症状缓解。
- 尼莫地平无论给药途径均发现缺氧信号,但其他药物包括对照药未发现。
- 口服尼卡地平未发现缺氧信号。
关键数值与推荐
- 使用信息成分(IC)及其95%可信区间下限评估不成比例性。
临床怎么用
- 临床使用静脉DCCI时应监测缺氧相关症状,尤其在高危患者中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Due to their negative effects on hypoxic pulmonary vasoconstriction, dihydropyridine calcium channel inhibitors (DCCIs) can lead to hypoxia in patients with a pulmonary shunt. To date, only preclinical studies and case reports have focused on this potential adverse drug reaction. We aimed to assess the reporting association between DCCIs and hypoxia using the World Health Organization pharmacovigilance database (VigiBase). We performed a disproportionality analysis to evaluate the strength of the reporting association between i.v. clevidipine and nicardipine, thought to be a surrogate of patients in the intensive care unit, and hypoxia. The information component and the lower end of its 95% credibility interval were used to evaluate disproportionality. A description of the cases was made. Secondary outcomes included the association between all DCCIs and hypoxia compared with other treatments with similar indications, urapidil and labetalol, regardless of the route of administration. Association between oral nicardipine and hypoxia was also searched. A statistically significant signal of hypoxia was found for intravenous clevidipine and nicardipine. The time to onset was reported with a median of 2 days (interquartile range 1.5-4.5). Four dechallenges were performed with intravenous nicardipine, leading to the resolution of the symptoms. Regardless of the route of administration, a signal of hypoxia was also found for nimodipine but not for other drugs, including comparators. For nicardipine no signal of hypoxia was found with the oral route of administration. Our pharmacovigilance database analysis showed a significant association between the use of intravenous DCCIs and hypoxia.
引用
- Chrétien B, Decros JB, Suard F, et al. Hypoxia Associated With Dihydropyridine Calcium Channel Inhibitors: A Pharmacovigilance Study in VigiBase. Clin Pharmacol Ther. 2023. PMID: 37309986. doi:10.1002/cpt.2970
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。